松龄血脉康胶囊治疗老年稳定性心绞痛临床观察

Therapeutic effect of Songlingxuemaikang capsule in elderly patients with stable angina

将82例接受常规治疗的心绞痛患者按系统随机方法分为正常组（40例）和对照组（42例），治疗组加用松龄血脉康胶囊，治疗12周，分别进行治疗前后心绞痛分级、超敏C反应蛋白、血压水平及中文版SF-36量表生存质量评估的比较。两组心绞痛分级、超敏C反应蛋白、血压水平均有明显降低，生存质量均明显提高，治疗组效果较对照组明显，差异有统计学意义（P〈0．05）。提示在常规西药治疗基础上加用松龄血脉康胶囊能进一步改善老年稳定性心绞痛患者缺血性胸痛。

Eighty two patients aged 60 or over with stable angina pectoris were randomized to control group （n = 42, receiving conventional western medicine ） and treatment group （n = 40, receiving 1.5 g Songlingxuemaikang capsules three times a day in addition to western medicine） . The treatment was lasted for 12 weeks, angina classification of CCS, hs-CRP, blood pressure levels and SF-36 （36-item short form） of the patients were evaluated before and after the treatment. The degrees of angina pectoris in angina classification of CCS, hs-CRP and blood pressure levels decreased, and the quality of life was improved in both groups; but more markedly in treatment group than those in control group （P 〈 0.05 ） . Songlingxuemaikang capsule combined with conventional western medicine can effectively relieve the symptoms of ischemic chest pain in elderly patients with stable angina pectoris, which is associated with blood pressure reduction and life quality improvement.